AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01894607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEFINITY
Description: During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier.
Study NCT01894607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
Study NCT00849940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAS NIRS FORE-SIGHT oximeter
Description: Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
Study NCT00629044 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessing the blood level of cholesterol 24 S Hydroxylase
Description: Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
Study NCT00629044 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessing the blood level of cholesterol 24 S hydroxylase
Description: Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
Study NCT00629044 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: assessing the blood level of cholesterol 24 S hydroxylase
Description: Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
Study NCT02662972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Study NCT01490775 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: no access to eMedonline
Description: patients will be followed for 3 months but will not use eMedonline
Study NCT01490775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eMedonline access
Description: patients will be given access to eMedonline use for 3 months
Study NCT03824041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia full spectrum - half dose
Description: Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
Study NCT03824041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aronia full spectrum - full dose
Description: Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
Study NCT03824041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
Study NCT04896996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole eggs
Description: whole eggs
Study NCT04896996 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: yolk-free egg substitutes
Description: yolk-free egg substitutes
Study NCT03659318 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted TKA
Description: Total knee arthroplasty is carried out with help of robotic surgery system, using a Robodoc system. CT-based preoperative planning using ORTHODOC (Integrated Surgical Technology Corp) performed in the first step before the day of surgery, and the robotic-assisted surgery using the ROBODOC surgical assistance in the second step. The bone markers are registered to the computer, and the computer arm does all the cutting and preparation of bones. This is in contrast to conventional jigs and cutting blocks. Actual implantation of the implants is done by a surgeon. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
Study NCT03659318 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional TKA
Description: Total knee arthroplasty is carried out with classical, conventional, manual method. A surgeon measures the angle, length of the cuts with bone landmarks and specialized surgical instruments. After all the cuts actual implantation is done. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
Study NCT00416208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
Study NCT03467347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VR: 200 mg DPV + 320 mg LNG
Description: One silicone elastomer vaginal ring (VR) containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)
Study NCT04520607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Healthcare professional-administered intra-articular injection of vehicle.
Study NCT04520607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorecivivint
Description: Healthcare professional-administered intra-articular injections of lorecivivint.
Study NCT00556075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 25 mg
Description: 1 capsule daily for 4 months
Study NCT00556075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 4 months
Study NCT00556075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 50 mg
Description: 2 capsules daily for 4 months
Study NCT03760991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE (U300)
Description: Pharmaceutical form: Solution for injection in a prefilled pen~Route of administration: Subcutaneous
Study NCT05149053 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed Collagen
Description: Active product was composed of Hydrolyzed Collagen, lemon flavoring, anhydrous citric acid (acidifier), calcium ascorbate (vitamin C), sucralose (sweetener) and stevia (sweetener). One 10.728 g dose provides 10 g of HC and 80 mg of vitamin C.
Study NCT05149053 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo packet contained sucralose (sweetener) and stevia (sweetener) in identical proportions to the active preparation.
Study NCT01128049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Subjective Questionnaire
Description: The team will use a one page questionnaire to obtain subjective input before the first set of measurements and after instilling the Saline drop.
Study NCT01128049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement with wavefront sensor (right eye, then left eye)
Description: The wavefront instrument measures the eye's ability to create a sharp image by briefly shining a laser light from the wavefront sensor into the eye and measuring the light that bounces back through the cornea. For these measurements, subjects will sit on a chair and be instructed to place their chin in a chin rest and lean their forehead against a forehead rest. The subject will be instructed to hold his/her head steady, look in a certain direction, blink or not blink. We will obtain the measurements over a short period of up to approximately 45 seconds. We will start recording data asking the subject to either blink naturally or to hold his/her eye open for a few (up to 10) seconds, and repeat the blink and hold sequence usually for up to four times.
Study NCT01128049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Instill Saline Drop
Description: One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
Study NCT02783365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photo-elicitation and online group support
Description: See above information.
Study NCT02451059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WE CARE survey
Description: The WE CARE survey, consists of 14 questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language). The survey will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age. The office staff will instruct parents to give the WE CARE survey, along with the developmental screening tool, to their child's provider at the visit.
Study NCT02451059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WE CARE Community Resource Handout
Description: Providers will be trained to review the WE CARE survey at health supervision visits and generate referrals thru the EMR. Specifically, they will receive a one-hour teaching session one week prior to the study implementation. The goals for the session will include providing an overview of pediatric practice guidelines, introducing the WE CARE survey, reviewing the referral process, and discussing the role of peer patient navigators. Study staff will conduct periodic booster sessions; study staff will also train new providers should there be staff turnover
Study NCT02451059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: The peer patient navigator will offer guidance to families with accessing community resources. They will be available at least .5 days per week at intervention health centers to meet with families and offer guidance as well as be available via a hotline number. The navigator will speak with families and offer guidance on community resources and offer assistance with completing applications. In addition, they will offer to schedule and, if desired, accompany parents to the agencies. Interpreter services will be utilized at the health centers in case the navigator does not speak the parent's language. The navigator will also place an update note in the EMR within 1-month post-visit and one week after any contact with families.
Study NCT01668303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Miami Juvenile Drug Court-MDFT
Description: MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
Study NCT01668303 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Miami Juvenile Drug Court -TAU
Description: Each client is provided with a primary outpatient counselor who develops a treatment plan to address long-range goals. Family members are included in an assessment and treatment planning session at the beginning of treatment, but no formal family therapy is provided. Group therapy topics include self-esteem enhancement, decision-making skills, stress/anger management, communication skills, health education, teen pregnancy prevention, and occupational/career planning.
Study NCT00644696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan and Bortezomib
Description: Dose level-1a: IV Irinotecan 30 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-1: IV Irinotecan 35 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-2: IV Irinotecan 40 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-3: IV Irinotecan 45 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-4: IV Irinotecan 50 mg/m2/day, IV bortezomib 1.2mg/m2/day
Study NCT04406766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected nutrition pump system
Description: For the patient, it consists of the installation of the connected pump at his home for a duration of one month.~Infusion data and events will be continuously collected and transmitted by the 4 different modes (LoRaAN, BLE , GSM and multimodality).Transmitted data won't be used to change the follow up of the patient.~At the end of the month, patients will be solicited by an ergonomic engineer to complete a specific questionnaire in order to evaluate the future acceptability of the proposed solution.
Study NCT01436526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)
Study NCT01954966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Participants will consume four pills of Progesterone over a period of four days. Participants will be asked to remain abstinent from smoking while taking Progesterone.
Study NCT01954966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.
Study NCT05366101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril/Valsartan
Description: Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
Study NCT05366101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
Study NCT03251391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation Program
Description: Program will involve 36 sessions. These will be scheduled as 3 sessions per week. If you cannot complete 3 sessions per week the 36 sessions could be spread out over 6 months.~Each session will last between 30-60 minutes. Sessions will involve aerobic activity, diet/nutritional counseling, and smoking cessation information.
Study NCT03251391 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Participants will be asked to complete tests and questionnaires that would normally be done for their condition.
Study NCT01174732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol inhalation powder
Description: A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation
Study NCT01174732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol inhalation powder
Description: A006 albuterol inhalation powder, 180 mcg/inhalation, 1 inhalation
Study NCT01174732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol inhalation powder
Description: A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
Study NCT01174732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol inhalation powder
Description: A006 albuterol inhalation powder, 180 mcg/inhalation, 2 inhalations
Study NCT01174732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, lactose inhalation carrier
Study NCT01174732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol inhalation aerosol
Description: albuterol inhalation aerosol, 90 mcg/inhalation, 2 inhalations
Study NCT01174732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol inhalation aerosol
Description: albuterol inhalation aerosol, 90 mcg/inhalation, 4 inhalations
Study NCT01436526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)
Study NCT00395746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfonylurea
Description: SU agent
Study NCT00395746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sulfonylurea
Description: SU agent
Study NCT00395746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
Study NCT00395746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
Study NCT04918706 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Allogeneic MSC
Description: These MSCs will originate from bone marrow that will be aspirated from healthy volunteer donors screened by a trained physician of the center for stem cell therapy of LUMC
Study NCT04918706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be an equivalent volume NaCl 0,9% and DMSO 5%
Study NCT03649074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AKL-T01
Description: AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task.
Study NCT03826719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607QIV
Description: Purified inactivated influenza virus surface antigens of four strains(quadrivalent)
Study NCT03826719 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal
Description: Influenza virus surface antigens of three strains(trivalent)
Study NCT01739166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice-tailored intervention to increase rates of targeted services
Description: Over a 6 month period, the Practice Facilitator (PF), offers individualized suggestions, strategies and tools for streamlining processes and incorporating new ideas into the flow of a practice's work day to increase their rates of delivery of the 3 targeted services of lead screening, obesity detection and dental decay prevention.~During the intervention visits the PF reviews a small number of recent well-visit charts. This allows for rapid feedback to a practice on their progress as they work toward reaching outcome measures. It also provides 'real time' feedback regarding the degree to which suggested interventions are working, allowing the PF to change the approach as needed.
Study NCT00599066 — intervention group
Intervention type: DEVICE
Intervention: study cases
Description: Application of a second M-Entropy probe on the forehead of the patient, which will happen in the OR along with the application of other monitors immediately before induction of general anesthesia.
Study NCT01691794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Study NCT01220518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
Study NCT01812434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 20mg three time daily for 28 days
Study NCT01812434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 mg three times daily for 28 days
Study NCT04325243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Description: 50 mg oral Sildenafil tablet
Study NCT04325243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: placebo tablets of the same shape, color and size of Sildenafil tablets manufactured in the Department of Pharmaceuticals, Faculty of Pharmacy
Study NCT00766363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124 (0.1 mg/day)
Description: EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
Study NCT00766363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124 (0.3 mg/day)
Description: EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
Study NCT00766363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6124 (1.0 mg/day)
Description: EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
Study NCT00766363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Matching placebo was administered as one capsule per day for 28 days.
Study NCT00766363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
Study NCT01691794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Study NCT00141102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Participants are assigned to one of two groups in parallel for the duration of the study
Study NCT00141102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac + Omeprazole
Description: Participants are assigned to one of two groups in parallel for the duration of the study
Study NCT02719821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral techniques
Description: Learning behavioral techniques designed to improve nighttime sleep quality and daytime activity for approximately 45-60 minutes on three occasions.~Device: Actiwatch-2 (Philips Respironics)
Study NCT00532662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S(+)-ketamine
Description: epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia